BACKGROUND: No consensus has been reached on the feasibility and efficacy of surgery for lymph node metastases (LNM) from @entity157 ( @entity157 ). METHODS: Of 2189 @entity1 with @entity157 treated at our hospital between July 1992 and March 2008, we retrospectively reviewed the medical dossiers of the 18 @entity1 (0.8%) who underwent lymph node resection and were pathologically diagnosed to have LNM from @entity157 . The surgical procedure for LNM was selective lymphadenectomy of those lymph nodes suspected to harbor @entity3 . The feasibility and efficacy of selective lymphadenectomy was examined, and clinicopathological factors were analyzed with the aim of determining which @entity1 would most benefit from surgery. RESULTS: Eighteen @entity1 underwent surgery without mortality or @entity1578 . Morbidities were found in four @entity1 (22.2%). The @entity1349 ( @entity1349 ) after surgery was 29  months [95% confidence interval (CI) 21-38  months). The 1-, 3-, and 5-year overall survival rates were 85, 42, 21%. The median progression-free survival (PFS) after surgery was 6  months (95% CI 1-11  months), and the median extrahepatic PFS was 16  months (95% CI 13-18  months). Single LNM was the only favorable prognostic factor after surgery (Hazard ratio 0.082, 95% CI 0.008-0.83). CONCLUSION: Selective lymphadenectomy of LNM from @entity157 was a feasible and efficacious procedure. Survival rates can be expected to improve after selective lymphadenectomy of single LNM.

Surgical treatment of lymph node metastases from XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1578 :: ('MESH:D017093', 'Disease') :: ['liver failure'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['median survival time', 'MST']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
